ERBB2 and breast cancer: Trastuzumab-resistant human epidermal growth factor receptor 2 (HER2+) breast cancers drive glycolysis through 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3)-mediated fructose-2,6-bisphosphate synthesis [37].